{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-026689","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2022-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.345425+00:00","generated_at":"2026-06-24T08:11:45.930464+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Viking Therapeutics Q2 net loss $17.4M ($0.23/sh); cash $169M; pipeline milestones on track","bullets":["Net loss of $17.4M ($0.23 per share) vs $15.4M ($0.20) in Q2 2021; R&D expense $13.5M, G&A $4.1M.","Cash, cash equivalents and short-term investments at $169M as of June 30, 2022.","VK2809 Phase 2b VOYAGE study for NASH/fibrosis; enrollment completion expected in 4Q 2022.","Phase 1 study of dual GLP-1/GIP agonist VK2735 ongoing; initial results expected by year-end 2022.","FDA clinical hold on VK0214 Phase 1b for X-ALD lifted; dosing to resume, data expected 1H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-026689","json":"https://secwatch.observer/filing/0001564590-22-026689.json","markdown":"https://secwatch.observer/filing/0001564590-22-026689.md","text":"https://secwatch.observer/filing/0001564590-22-026689.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000156459022026689/0001564590-22-026689-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000156459022026689/vktx-8k_20220727.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T08:11:45.930464+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}